Phase i, pharmacokinetic, and biological study of erlotinib in combination with paclitaxel and carboplatin in patients with advanced solid tumorsPATNAIK, Amita; WOOD, Debra; WOLF, Julie et al.Clinical cancer research. 2006, Vol 12, Num 24, pp 7406-7413, issn 1078-0432, 8 p.Article

Phase I and pharmacokinetic study of a low-clearance, unilamellar liposomal formulation of lurtotecan, a topoisomerase 1 inhibitor, in patients with advanced leukemiaGILES, Francis J; TALLMAN, Martin S; KANTARJIAN, Hagop M et al.Cancer. 2004, Vol 100, Num 7, pp 1449-1458, issn 0008-543X, 10 p.Article

The effects of CYP3A4 inhibition on erlotinib pharmacokinetics : computer-based simulation (SimCYP™) predicts in vivo metabolic inhibitionRAKHIT, Ashok; PANTZE, Michael P; FETTNER, Scott et al.European journal of clinical pharmacology. 2008, Vol 64, Num 1, pp 31-41, issn 0031-6970, 11 p.Article

Epidermal growth factor receptor tyrosine kinase inhibition represses cyclin D1 in aerodigestive tract cancersPETTY, W. Jeffrey; DRAGNEV, Konstantin H; IWATA, Kenneth K et al.Clinical cancer research. 2004, Vol 10, Num 22, pp 7547-7554, issn 1078-0432, 8 p.Article

Erlotinib plus gemcitabine in patients with unresectable pancreatic cancer and other solid tumors: Phase IB trialDRAGOVICH, Tomislav; HUBERMAN, Mark; VON HOFF, Daniel D et al.Cancer chemotherapy and pharmacology. 2007, Vol 60, Num 2, pp 295-303, issn 0344-5704, 9 p.Article

Metabolism and excretion of erlotinib, a small molecule inhibitor of epidermal growth factor receptor tyrosine kinase, in healthy male volunteersJIE LING; JOHNSON, Kim A; ZHUANG MIAO et al.Drug metabolism and disposition. 2006, Vol 34, Num 3, pp 420-426, issn 0090-9556, 7 p.Article

Phase I and pharmacologic study of liposomal lurtotecan, NX 211: Urinary excretion predicts hematologic toxicityKEHRER, Diederik F. S; BOS, Annelies M; VERWEIJ, Jaap et al.Journal of clinical oncology. 2002, Vol 20, Num 5, pp 1222-1231, issn 0732-183XArticle

Pediatric Phase I and Pharmacokinetic Study of Erlotinib Followed by the Combination of Erlotinib and Temozolomide : A Children's Oncology Group Phase I Consortium StudyJAKACKI, Regina I; HAMILTON, Marta; GILBERTSON, Richard J et al.Journal of clinical oncology. 2008, Vol 26, Num 30, pp 4921-4927, issn 0732-183X, 7 p.Article

Effects of smoking on the pharmacokinetics of erlotinibHAMILTON, Marta; WOLF, Julie L; RUSK, Jason et al.Clinical cancer research. 2006, Vol 12, Num 7, pp 2166-2171, issn 1078-0432, 6 p., 1Article

Pharmacokinetics of tenofovir in breast milk of lactating rhesus macaquesVAN ROMPAY, Koen K. A; HAMILTON, Marta; KEARNEY, Brian et al.Antimicrobial agents and chemotherapy. 2005, Vol 49, Num 5, pp 2093-2094, issn 0066-4804, 2 p.Article

Structural identification and biological activity of 7-methyl-10,11-ethylenedioxy-20(S)-camptothecin, a photodegradant of lurtotecanLOOS, Walter J; VERWEIJ, Jaap; KEHRER, Diederik F. S et al.Clinical cancer research. 2002, Vol 8, Num 3, pp 856-862, issn 1078-0432Article

The effect of rifampicin, a prototypical CYP3A4 inducer, on erlotinib pharmacokinetics in healthy subjectsHAMILTON, Marta; WOLF, Julie L; DROLET, Daniel W et al.Cancer chemotherapy and pharmacology. 2014, Vol 73, Num 3, pp 613-621, issn 0344-5704, 9 p.Article

Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure-safety relationship in patients with non-small cell lung cancerLU, Jian-Feng; EPPLER, Steve M; WOLF, Julie et al.Clinical pharmacology and therapeutics. 2006, Vol 80, Num 2, pp 136-145, issn 0009-9236, 10 p.Article

Randomized trial of two intravenous schedules of the topoisomerase I inhibitor liposomal lurtotecan in women with relapsed epithelial ovarian cancer: A trial of the National Cancer Institute of Canada Clinical Trials GroupDARK, Graham G; CALVERT, A. Hilary; TRUDEAU, Marc et al.Journal of clinical oncology. 2005, Vol 23, Num 9, pp 1859-1866, issn 0732-183X, 8 p.Article

Biological effects of short-term or prolonged administration of 9-[2-(phosphonomethoxy)propyl]adenine (tenofovir) to newborn and infant rhesus macaquesVAN ROMPAY, Koen K. A; BRIGNOLO, Laurie L; DEARMAN, Trish G et al.Antimicrobial agents and chemotherapy. 2004, Vol 48, Num 5, pp 1469-1487, issn 0066-4804, 19 p.Article